News & Updates
Filter by Specialty:
COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC
The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.
COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC
04 Nov 2022
Once-a-day pill as switch option receives thumbs up across multiple HIV populations
Switching to the once-a-day, fixed-dose pill that contains bictegravir, emtricitabine, and tenofovir (BIC/FTC/TAF) appears to be safe and effective in older HIV patients and in people living with HIV (PLHIV) with pretreatment or treatment-acquired resistance, in addition to yielding metabolic benefits, according to studies presented at HIV Glasgow 2022.
Once-a-day pill as switch option receives thumbs up across multiple HIV populations
04 Nov 2022
Detectable viral loads persist in one-third of PLHIV in Asia-Pacific region
Between 2015 and 2020, nearly a third of people living with HIV (PLHIV) in Asia-Pacific countries still show a detectable viral load, according to a study presented at the HIV Glasgow 2022 Congress.
